GT Biopharma Inc (GTBP)

[oxis007]

I think Oxis will be acquired in by '19 by a large pharmaceutical company (Pfizer) assuming data for OXS-1550 is promising and TRiKe clinical trials go as planned

Here are my reasons

OXS-1550 Phase two data will be available in June of '18

By the end of this year Oxis will have at least two additional drugs in the clinic (Not including the drugs acquired in their recent acquisition.)

OXS-3550 for liquid tumors. The TRiKE platform has shown promising in vivo data compared to
BiKEs . (The addition of Il-15 created NK cell proliferation resulting in 60-70% remission vs 30-
50% for BiKE)

OXS-4550 Again using the TRiKE platform In Vivo data isn't yet, however Dr. Miller assured me in
the email that they've made significant progress with it.

OXS-4235 There's a chance (albeit slim) that this Multiple Myeloma drugs enters the clinic this
year


Here's what I think will happen over the next few months,

Oxis will uplist to the nasdaq and will change the company name. In order to do this they will do
a reverse split, then fund operations through selling shares at a price of $10.00 per share.

However, unfortunately for us, I believe they won't announce that Mace Rothenberg is the CMO
and instead save that for after the reverse split when they uplist.

Initiate the two clinical trials. The one trial OXS-3550 is a partnership with Altor Bioscience
which is owned by Dr. Patrick Soon Shiong.

Towards the end of the year and more probably next year, Pfizer will license the TRiKE platform
from Oxis

Final thoughts

Why do I think a top oncologist like Mace Rotherberg is even bothering with a small biotech
company like Oxis? Because he sees the potential the TRiKE platform and for the CNS piepline.
This isn't the first time Mace has done this. According to the Wall Street Journal, in November of
2011 Dr. Rothenberg. Flew out to California to look at promising clinical data for the compound
PD-0332991. However Pfizer wasn't willing to fund the continuing clinical trials and so he raised
money from outside investors. PD-0332991 went on to become ibrance and was initially licensed
to Pfizer and then Pfizer later on acquired the company in its entirety. But this isn't it, prior to
this, Pfizer had licensed an alzheimers drug named Dimebon from this company for 225 million.
This explains why Oxis acquired Georgetown Translational Pharmaceuticals. So whats the name
of this company. Medivation, a company Pfizer acquired for 14 billion or $81.50 a share.

According to a press release from 05/05/2017 "Both our TriSpecific Killer Engager (TriKE) and
Bispecific Killer Engager (BiKE) platforms are applicable to solid tumors (80% of the
marketplace) and liquid tumors (20% of the market). In addition to our planned clinical
development program, our strategy will include potentially out-licensing the technology to
Pharma and other biotech companies for specific applications," said Oxis Chairman & Chief
Executive Officer Anthony Cataldo.
http://www.nasdaq.com/press-release/oxis-international-expands-its-stateoftheart-trike-
technology-portfolio-20170503-00696


And there's also this from Mase Rothernberg. Oxis' incoming CMO said: "The drugs in the Oxis
pipeline are at the forefront of targeted immunotherapeutics and represent the wave of the future.
The non-clinical and clinical data is impressive and validates this approach to cancer therapy.
Once approved, these agents will herald a major breakthrough in the field of immunotherapy and
offer patients hope against some of the most difficult diseases to treat."

Keep in mind this is the
guy who said "I think we have something special" his words not mine in regards to PD-0332991
according to the wall street journal. PD-0332991 went on to later become IBRANCE.